Marginal zone lymphomas: Factors that affect the final outcome

Ali Mazloom, L. Jeffrey Medeiros, Peter W. McLaughlin, Valerie Reed, Fernando F. Cabanillas, Luis E. Fayad, Barbara Pro, Graciela Gonzalez, Puneeth Iyengar, Diana L. Urbauer, Bouthaina S. Dabaja

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

BACKGROUND: A retrospective review and analysis of 275 patients with marginal zone lymphoma (MZL) was performed to determine prognostic factors. An effort was also made to establish a specific prognostic score for patients with extranodal MZL. METHODS: Patients were divided into 3 groups according to the type of MZL: extranodal, nodal, and splenic. Factors analyzed included age; gender; presence of B symptoms; Zubrod performance score; clinical stage; serum β2-microglobulin, lactate dehydrogenase, albumin, and hemoglobin levels; and presence of autoimmune disorder. RESULTS: The 5-year overall survival rates of patients with extranodal, nodal, and splenic MZL were 87%, 89%, and 93%, respectively (P = .95). On multivariate analysis, splenic MZL patients had the best prognosis (hazard ratio, 0.18; P = .018). An elevated serum β2-microglobulin level (P = .010), B symptoms (P = .021), and male gender (P = .036) were found to be correlated with decreased recurrence-free survival (RFS) on multivariate analysis. Using these 3 variables, a 3-tier prognostic scoring system was created for patients with extranodal MZL: low-risk with no adverse factors, intermediate-risk with 1 adverse factor, and high-risk with ≥2 adverse factors. The 5-year RFS rates for the low-risk, intermediate-risk, and high-risk groups were 80%, 71%, and 44%, respectively (P = .01). CONCLUSIONS: Patients with extranodal and nodal MZL have a similar prognosis, whereas patients with splenic MZL have a better prognosis despite the increased prevalence of negative prognostic indicators. With the use of 3 readily available factors, a prognostic scoring system was identified for patients with extranodal MZL.

Original languageEnglish (US)
Pages (from-to)4291-4298
Number of pages8
JournalCancer
Volume116
Issue number18
DOIs
StatePublished - Sep 15 2010

Fingerprint

Lymphoma
Multivariate Analysis
Survival Rate
Recurrence
Serum
Albumins
Hemoglobins
Survival

Keywords

  • Extranodal
  • Marginal zone lymphoma
  • Mucosa-associated lymphoid tissue
  • Nodal
  • Prognostic factors
  • Splenic

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Mazloom, A., Medeiros, L. J., McLaughlin, P. W., Reed, V., Cabanillas, F. F., Fayad, L. E., ... Dabaja, B. S. (2010). Marginal zone lymphomas: Factors that affect the final outcome. Cancer, 116(18), 4291-4298. https://doi.org/10.1002/cncr.25325

Marginal zone lymphomas : Factors that affect the final outcome. / Mazloom, Ali; Medeiros, L. Jeffrey; McLaughlin, Peter W.; Reed, Valerie; Cabanillas, Fernando F.; Fayad, Luis E.; Pro, Barbara; Gonzalez, Graciela; Iyengar, Puneeth; Urbauer, Diana L.; Dabaja, Bouthaina S.

In: Cancer, Vol. 116, No. 18, 15.09.2010, p. 4291-4298.

Research output: Contribution to journalArticle

Mazloom, A, Medeiros, LJ, McLaughlin, PW, Reed, V, Cabanillas, FF, Fayad, LE, Pro, B, Gonzalez, G, Iyengar, P, Urbauer, DL & Dabaja, BS 2010, 'Marginal zone lymphomas: Factors that affect the final outcome', Cancer, vol. 116, no. 18, pp. 4291-4298. https://doi.org/10.1002/cncr.25325
Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE et al. Marginal zone lymphomas: Factors that affect the final outcome. Cancer. 2010 Sep 15;116(18):4291-4298. https://doi.org/10.1002/cncr.25325
Mazloom, Ali ; Medeiros, L. Jeffrey ; McLaughlin, Peter W. ; Reed, Valerie ; Cabanillas, Fernando F. ; Fayad, Luis E. ; Pro, Barbara ; Gonzalez, Graciela ; Iyengar, Puneeth ; Urbauer, Diana L. ; Dabaja, Bouthaina S. / Marginal zone lymphomas : Factors that affect the final outcome. In: Cancer. 2010 ; Vol. 116, No. 18. pp. 4291-4298.
@article{08ea4bce7c314edda9bfb0d014f8d844,
title = "Marginal zone lymphomas: Factors that affect the final outcome",
abstract = "BACKGROUND: A retrospective review and analysis of 275 patients with marginal zone lymphoma (MZL) was performed to determine prognostic factors. An effort was also made to establish a specific prognostic score for patients with extranodal MZL. METHODS: Patients were divided into 3 groups according to the type of MZL: extranodal, nodal, and splenic. Factors analyzed included age; gender; presence of B symptoms; Zubrod performance score; clinical stage; serum β2-microglobulin, lactate dehydrogenase, albumin, and hemoglobin levels; and presence of autoimmune disorder. RESULTS: The 5-year overall survival rates of patients with extranodal, nodal, and splenic MZL were 87{\%}, 89{\%}, and 93{\%}, respectively (P = .95). On multivariate analysis, splenic MZL patients had the best prognosis (hazard ratio, 0.18; P = .018). An elevated serum β2-microglobulin level (P = .010), B symptoms (P = .021), and male gender (P = .036) were found to be correlated with decreased recurrence-free survival (RFS) on multivariate analysis. Using these 3 variables, a 3-tier prognostic scoring system was created for patients with extranodal MZL: low-risk with no adverse factors, intermediate-risk with 1 adverse factor, and high-risk with ≥2 adverse factors. The 5-year RFS rates for the low-risk, intermediate-risk, and high-risk groups were 80{\%}, 71{\%}, and 44{\%}, respectively (P = .01). CONCLUSIONS: Patients with extranodal and nodal MZL have a similar prognosis, whereas patients with splenic MZL have a better prognosis despite the increased prevalence of negative prognostic indicators. With the use of 3 readily available factors, a prognostic scoring system was identified for patients with extranodal MZL.",
keywords = "Extranodal, Marginal zone lymphoma, Mucosa-associated lymphoid tissue, Nodal, Prognostic factors, Splenic",
author = "Ali Mazloom and Medeiros, {L. Jeffrey} and McLaughlin, {Peter W.} and Valerie Reed and Cabanillas, {Fernando F.} and Fayad, {Luis E.} and Barbara Pro and Graciela Gonzalez and Puneeth Iyengar and Urbauer, {Diana L.} and Dabaja, {Bouthaina S.}",
year = "2010",
month = "9",
day = "15",
doi = "10.1002/cncr.25325",
language = "English (US)",
volume = "116",
pages = "4291--4298",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "18",

}

TY - JOUR

T1 - Marginal zone lymphomas

T2 - Factors that affect the final outcome

AU - Mazloom, Ali

AU - Medeiros, L. Jeffrey

AU - McLaughlin, Peter W.

AU - Reed, Valerie

AU - Cabanillas, Fernando F.

AU - Fayad, Luis E.

AU - Pro, Barbara

AU - Gonzalez, Graciela

AU - Iyengar, Puneeth

AU - Urbauer, Diana L.

AU - Dabaja, Bouthaina S.

PY - 2010/9/15

Y1 - 2010/9/15

N2 - BACKGROUND: A retrospective review and analysis of 275 patients with marginal zone lymphoma (MZL) was performed to determine prognostic factors. An effort was also made to establish a specific prognostic score for patients with extranodal MZL. METHODS: Patients were divided into 3 groups according to the type of MZL: extranodal, nodal, and splenic. Factors analyzed included age; gender; presence of B symptoms; Zubrod performance score; clinical stage; serum β2-microglobulin, lactate dehydrogenase, albumin, and hemoglobin levels; and presence of autoimmune disorder. RESULTS: The 5-year overall survival rates of patients with extranodal, nodal, and splenic MZL were 87%, 89%, and 93%, respectively (P = .95). On multivariate analysis, splenic MZL patients had the best prognosis (hazard ratio, 0.18; P = .018). An elevated serum β2-microglobulin level (P = .010), B symptoms (P = .021), and male gender (P = .036) were found to be correlated with decreased recurrence-free survival (RFS) on multivariate analysis. Using these 3 variables, a 3-tier prognostic scoring system was created for patients with extranodal MZL: low-risk with no adverse factors, intermediate-risk with 1 adverse factor, and high-risk with ≥2 adverse factors. The 5-year RFS rates for the low-risk, intermediate-risk, and high-risk groups were 80%, 71%, and 44%, respectively (P = .01). CONCLUSIONS: Patients with extranodal and nodal MZL have a similar prognosis, whereas patients with splenic MZL have a better prognosis despite the increased prevalence of negative prognostic indicators. With the use of 3 readily available factors, a prognostic scoring system was identified for patients with extranodal MZL.

AB - BACKGROUND: A retrospective review and analysis of 275 patients with marginal zone lymphoma (MZL) was performed to determine prognostic factors. An effort was also made to establish a specific prognostic score for patients with extranodal MZL. METHODS: Patients were divided into 3 groups according to the type of MZL: extranodal, nodal, and splenic. Factors analyzed included age; gender; presence of B symptoms; Zubrod performance score; clinical stage; serum β2-microglobulin, lactate dehydrogenase, albumin, and hemoglobin levels; and presence of autoimmune disorder. RESULTS: The 5-year overall survival rates of patients with extranodal, nodal, and splenic MZL were 87%, 89%, and 93%, respectively (P = .95). On multivariate analysis, splenic MZL patients had the best prognosis (hazard ratio, 0.18; P = .018). An elevated serum β2-microglobulin level (P = .010), B symptoms (P = .021), and male gender (P = .036) were found to be correlated with decreased recurrence-free survival (RFS) on multivariate analysis. Using these 3 variables, a 3-tier prognostic scoring system was created for patients with extranodal MZL: low-risk with no adverse factors, intermediate-risk with 1 adverse factor, and high-risk with ≥2 adverse factors. The 5-year RFS rates for the low-risk, intermediate-risk, and high-risk groups were 80%, 71%, and 44%, respectively (P = .01). CONCLUSIONS: Patients with extranodal and nodal MZL have a similar prognosis, whereas patients with splenic MZL have a better prognosis despite the increased prevalence of negative prognostic indicators. With the use of 3 readily available factors, a prognostic scoring system was identified for patients with extranodal MZL.

KW - Extranodal

KW - Marginal zone lymphoma

KW - Mucosa-associated lymphoid tissue

KW - Nodal

KW - Prognostic factors

KW - Splenic

UR - http://www.scopus.com/inward/record.url?scp=77957356730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957356730&partnerID=8YFLogxK

U2 - 10.1002/cncr.25325

DO - 10.1002/cncr.25325

M3 - Article

C2 - 20549822

AN - SCOPUS:77957356730

VL - 116

SP - 4291

EP - 4298

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 18

ER -